

SEATTLE GENETICS, INC.

Nasdaq / SGEN / US8125781026

Company Profile

Business Summary

Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.

Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Number of employees : 759 persons.

Sales per Businesses

	2014		2015		Delta
	USD (in Million)	%	USD (in Million)	%	
Pharmaceutical Products	286.76	100%	336.80	100%	+14.86%

Sales per Regions

	2014		2015		Delta
	USD (in Million)	%	USD (in Million)	%	
United States	286.76	100%	336.80	100%	+14.86%

Upcoming events on SEATTLE GENETICS, INC.

04/28/16

Q1 2016 Earnings Release (Projected)

07/28/16

Interim 2016 Earnings Release (Projected)

10/27/16

Q3 2016 Earnings Release (Projected)

Past events on SEATTLE GENETICS, INC.

03/16/16 | 04:15pm

Barclays Global Health Care Conference

03/08/16 | 05:20pm


Cowen and Company Health Care Conference

02/11/16 | 06:00pm

Leerink Partners Global Health Care Conference

02/09/16 | 10:30pm

FY 2015 Earnings Call



Managers

Name	Age	Since	Title
Clay B. Siegall, PhD	55	1997	Chairman, President & Chief Executive Officer
Eric L. Dobmeier	47	2002	Chief Operating Officer
Todd E. Simpson, CPA	55	2005	Chief Financial Officer
Jonathan Drachman, MD	54	2013	Chief Medical Officer, EVP-Research & Development
Srini Akkaraju MD, PhD	48	2003	Independent Director

Shareholders

Name	Equities	%
Baker Bros. Advisors LP	43,269,888	30.9%
Baillie Gifford & Co.	17,152,807	12.3%
Fidelity Management & Research Co.	17,118,096	12.2%
PRIMECAP Management Co.	12,882,175	9.21%
The Vanguard Group, Inc.	6,881,088	4.92%

Company contact info

21823 30th Drive SE  
Bothell, WA 98021


Phone : +1.425.527.4000  
Fax : +1.425.527.4001  
Web : [www.seattlegenetics.com](http://www.seattlegenetics.com)

# SEATTLE GENETICS, INC.

Nasdaq / SGEN / US8125781026

## Financials and Forecast

### Income Statement Evolution : Past and Forecast




©4-traders.com - Thomson Reuters

### Annual Income Statement Data : Past and Forecast

Fiscal Period December	Actuals in M \$			Estimates in M \$		
	2013	2014	2015	2016	2017	2018
Sales	269	287	337	426	498	613
Operating income (EBITDA)	-54,2	-64,9	-106	-136	-140	-102
Operating profit (EBIT)	-62,9	-77,4	-121	-112	-87,6	-18,2
Pre-Tax Profit (EBT)	-62,5	-	-	-	-	-
Net income	-62,5	-76,1	-120	-136	-97,0	-16,7
P/E ratio	-78,2	-51,8	-48,3	-39,5	-54,1	-342
EPS ( \$ )	-0,51	-0,62	-0,93	-0,96	-0,70	-0,11
Dividend per Share ( \$ )	-	-	-	-	-	-
Yield	-	-	-	-	-	-
Reference price ( \$ )	39.89	32.13	44.88	37.93	37.93	37.93
Announcement Date	02/11/2014 09:05pm	02/10/2015 09:02pm	02/09/2016 09:02pm	-	-	-

### Finances - Leverage : Past and Forecast




©4-traders.com - Thomson Reuters

### Financial Ratios

Size	2016e	2017e
Capitalization	5 308 M\$	-
Entreprise Value (EV)	4 760 M\$	4 867 M\$
<b>Valuation</b>		
P/E ratio (Price / EPS)		
Capitalization / Revenue	12,5x	10,6x
EV / Revenue	11,2x	9,77x
EV / EBITDA	-35,1x	-34,7x
Yield (DPS / Price)	-	-
Price to book (Price / BVPS)	7,74x	9,96x
<b>Profitability</b>		
Operating Margin (EBIT / Sales)	-26,3%	-17,6%
operating Leverage (Delta EBIT / Delta Sales)	0,28x	1,27x
Net Margin (Net Profit / Revenue)	-31,9%	-19,5%
ROA (Net Profit / Asset)	-17,7%	-18,6%
ROE (Net Profit / Equities)	-21,9%	-23,8%
Rate of Dividend	-	-


Balance Sheet Analysis	2016e	2017e
CAPEX / Sales	3,28%	2,96%
Cash Flow / Sales	-23,4%	-18,6%
Capital Intensity (Assets / Sales)	1,80x	1,05x
Financial Leverage (Net Debt / EBITDA)	4,04x	3,14x

### Revenue Revisions



©4-traders.com - Thomson Reuters

### EPS Revisions




©4-traders.com - Thomson Reuters

# SEATTLE GENETICS, INC.

Nasdaq / SGEN / US8125781026

## Analysts' Consensus

### Evolution of the average consensus target price




©4-traders.com - Thomson Reuters

### Consensus

Sell ■ ■ ■ Buy


Mean consensus	OUTPERFORM
Number of Analysts	16
Average target price	43,9 \$
Last Close Price	37,9 \$
Spread / Highest target	71%
Spread / Average Target	16%
Spread / Lowest Target	-21%

### Consensus detail




©4-traders.com - Thomson Reuters

### Target Price consensus revisions : last 18 months



©4-traders.com - Thomson Reuters

### Consensus revision (last 18 months)




©4-traders.com - Thomson Reuters

# SEATTLE GENETICS, INC.

Nasdaq / SGEN / US8125781026

## Sector and Competitors

Chart Sector



### Subsector Biotechnology & Medical Research - NEC

	1st jan.	Capitalisation (M\$)	Growth (Revenue)	Profitability	Finances	Valuation	P/E ratio	EPS revision 4m.
SEATTLE GENETICS, INC.	-15.49%	5 308	██████████	██████████	██████████	██████████	-	██████████
INCYTE CORPORATION	-32.37%	15 326	██████████	██████████	██████████	██████████	██████████	██████████
CELLTRION, INC.	---%	11 119	██████████	██████████	██████	██████████	██████████	██████████
LONZA GROUP AG	-0.67%	9 113	██████████	██████████	██████	██████████	██████	██████████
QUINTILES TRANSNATIONAL HOL..	2.23%	8 388	██████████	██████████	██████████	██████████	██████████	██████████
ALNYLAM PHARMACEUTICALS, IN..	-22.46%	6 231	██████████	██████████	██████████	██████████	-	██████████
ALKERMES PLC	-51.74%	5 776	██████████	██████████	██████████	██████████	-	██████████
IONIS PHARMACEUTICALS INC	-31.75%	5 614	██████████	██████████	-	-	-	██████████
QIAGEN NV	-20.47%	5 499	██████████	██████████	██████████	██████████	██████████	██████████
UNITED THERAPEUTICS CORPORA..	-26.22%	5 240	██████████	██████████	██████████	██████████	██████████	██████████
ICON PLC	-2.14%	4 182	██████████	██████████	██████████	██████████	██████████	██████████
INTREXON CORP	16.45%	4 100	██████████	██████████	-	-	-	██████████
CHARLES RIVER LABORATORIES	2.29%	3 873	██████████	██████████	██████████	██████████	██████████	██████████
ACADIA PHARMACEUTICALS INC.	-7.83%	3 701	██████████	██████████	██████████	-	-	██████████
PAREXEL INTERNATIONAL CORPO..	-1.64%	3 597	██████████	██████████	██████████	██████████	██████████	██████████
BIO-TECHNE CORP	2.39%	3 526	██████████	██████████	██████████	-	██████████	██████████
ANACOR PHARMACEUTICALS INC	-35.19%	3 284	██████████	██████████	-	-	-	██████████
PRA HEALTH SCIENCES INC	3.34%	2 820	██████████	██████████	██████	██████████	██████████	██████████
LIGAND PHARMACEUTICALS INC.	8.16%	2 436	██████████	██████████	██████████	-	██████████	██████████
INC RESEARCH HOLDINGS INC	-12.64%	2 394	██████████	██████████	██████████	██████	██████████	██████████
NEKTAR THERAPEUTICS	-9.14%	2 083	██████	██████████	-	-	-	██████████

**Best Growth (Revenue) :** ACADIA Pharmaceuticals  
**Best Profitability :** Ligand Pharmaceuticals  
**Best Situation Fi. :** ACADIA Pharmaceuticals  
**Best EPS revision 4m. :** PRA Health Sciences Inc  
**Best Valuation :** PAREXEL International C  
**Best Investor Rating :** ICON PLC

**Worst Growth (Revenue) :** United Therapeutics Cor  
**Worst Profitability :** ACADIA Pharmaceuticals  
**Worst Situation Fi. :** Ionis Pharmaceuticals I  
**Worst EPS revision 4m. :** Anacor Pharmaceuticals  
**Worst Valuation :** Ionis Pharmaceuticals I  
**Worst Investor Rating :** Nektar Therapeutics

**Disclaimer :** 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

<http://www.4-traders.com>




## SEATTLE GENETICS, INC.


Nasdaq / SGEN / US8125781026

## Technical Analysis

## Daily chart



## Weekly chart



## Technical analysis trends

	Short Term	Mid-Term	Long Term
Trend	Bullish	Neutral	Bearish
Resistance	37,9	45,5	38,9
Spread/Res.	-3,2%	-19%	-5,5%
Spread/Supp.	9,1%	37%	28%
Support	33,6	26,9	28,6

## Indicators

STIM	
RSI 14 days	59.78
MA20	34.07
MA50	32.55
MA100	36.77
MA20 / Price	7.19%
MA50 / Price	11.33%
MA100 / Price	-0.16%

## Volumes

Session volume	1 478 358
Avg. Volume 20 sessions	1 234 721
Volume ratio	1.20
Session exchange	54 270 522\$
Avg. Exchange 20 sessions	45 326 608\$
Number of securities	139 932 886
Swapped fund session	1.06%

## Changes at 04/07 market close

5-day price change	+4.62%
Change as of January 1	-18.20%
1-year price change	+1.94%
10-year price change	+640.12%

## Extremes

10-year High (02/28/2014)	55.99
10-year Low (07/21/2006)	3.8

SEATTLE GENETICS, INC.  
Nasdaq / SGEN / US8125781026

Summary

Strengths

- The prospective high growth for the next fiscal years is among the main assets of the company.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

- Low profitability weakens the company.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
- The company has poor fundamentals for a short-term investment strategy.

Surperformance© ratings of Seattle Genetics, Inc.

	Overall rating
Trading Rating	☆☆☆☆☆☆
Investor Rating	☆☆☆☆☆☆
Growth (Revenue)	■■■■■■■■■
Valuation	■■■■■■■■■
Finances	■■■■■■■■■
Profitability	■■■■■■■■■
Earnings quality	■■■■■■■■■
Business Predictability	■■■■■■■■■
P/E ratio	-
Potential	■■■■■■■■■
Yield	-
Consensus	■■■■■■■■■
7 days EPS revision	■■■■■■■■■
4 months EPS revision	■■■■■■■■■
1 year EPS revision	■■■■■■■■■
4 months Revenue revision	■■■■■■■■■
1 year Revenue revision	■■■■■■■■■

Surperformance© rating of Seattle Genetics, Inc.

	Overall rating
Short Term Timing	■■■■■■■■■
Middle Term Timing	■■■■■■■■■
Long Term Timing	■■■■■■■■■
RSI	■■■■■■■■■
Bollinger Spread	■■■■■■■■■
Unusual Volumes	■■■■■■■■■
STIM	■■■■■■■■■